Prothena Corporation plc — Q1 2023 Form 10-Q Summary
Business Context and Reporting Period
Prothena is an Ireland-incorporated late-stage clinical biotechnology company focused on protein dysregulation and investigational therapies for neurodegenerative and amyloid diseases. The filing covers the unaudited quarter ended March 31, 2023, compared with the quarter ended March 31, 2022. Ordinary shares outstanding were 52.8 million at March 31, 2023, and 52.75 million at April 28, 2023.
Key programs include wholly owned birtamimab for AL amyloidosis and PRX012 and PRX123 for Alzheimer’s disease, together with partnered programs including prasinezumab with Roche and PRX005, TDP-43 and PRX019 programs with Bristol Myers Squibb. Novo Nordisk holds the ATTR amyloidosis business and related milestone rights.
Financial Performance and Liquidity
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Total revenue | $2.2 million | $1.2 million | Up 88% |
| Collaboration revenue | $2.1 million | $1.1 million | Up 92% |
| Research and development expense | $44.8 million | $27.3 million | Up 64% |
| General and administrative expense | $13.7 million | $11.8 million | Up 16% |
| Total operating expenses | $58.5 million | $39.1 million | Up 50% |
| Loss from operations | $(56.3) million | $(37.9) million | Higher loss |
| Net loss | $(46.9) million | $(36.3) million | Higher loss |
| Basic and diluted loss per share | $(0.89) | $(0.78) | Higher loss per share |
| Net cash used in operating activities | $(47.5) million | $(37.4) million | Higher cash use |
Interest income was $6.7 million, compared with $53,000 in the prior-year quarter, primarily reflecting higher interest rates and larger money market balances. This substantially offset operating losses but did not prevent a net loss. The filing does not present a conventional operating or gross margin because Prothena is a development-stage biotechnology company with minimal revenue and no commercial product sales.
Cash and cash equivalents were $686.2 million at March 31, 2023, compared with $710.4 million at December 31, 2022. Cash, cash equivalents and restricted cash totaled $688.4 million. Working capital was $651.5 million. Financing activities provided $23.3 million, including $20.7 million from the partial exercise of underwriters’ option shares in the December 2022 offering and $2.6 million from stock-option exercises.
The balance sheet shows no disclosed borrowings or senior debt. Total liabilities were $134.2 million, including $94.6 million of deferred revenue and $4.9 million of current lease liabilities. Deferred revenue includes $85.3 million related to outstanding BMS rights and $9.3 million of unsatisfied PRX005 development-services obligations.
Material Changes Versus the Prior Comparable Period
- Revenue increased $1.0 million, principally from higher BMS collaboration revenue recognized for PRX005 development services.
- R&D expense increased $17.5 million, driven primarily by higher PRX012 clinical-trial costs, personnel and share-based compensation, consulting, and PRX123 manufacturing costs; this was partly offset by lower birtamimab manufacturing costs.
- G&A expense increased $1.9 million, mainly from higher personnel, share-based compensation and legal expenses.
- Net loss increased $10.6 million and operating cash use increased $10.0 million.
- Share-based compensation expense increased to $8.8 million from $7.7 million. Outstanding options totaled 10.5 million at March 31, 2023, with a weighted-average exercise price of $26.78.
- Cash declined by $24.2 million during the quarter despite $23.3 million of financing inflows, reflecting continued development spending.
Guidance, Outlook, Risks and Unusual Items
- Management believes existing cash and cash equivalents are sufficient to meet obligations for at least the next twelve months, but expects additional capital will be required to continue development and potential commercialization activities.
- Full-year 2023 net cash used in operating and investing activities is expected to be approximately $213 million to $229 million.
- Management expects 2023 R&D expense to increase from 2022 because of higher personnel and share-based compensation costs, clinical-trial spending and manufacturing costs. G&A expense is also expected to increase.
- Topline data from the birtamimab AFFIRM-AL Phase 3 study and Roche’s prasinezumab PADOVA Phase 2b study are expected in 2024. Topline data from the PRX005 multiple-ascending-dose Phase 1 study and PRX012 Phase 1 studies are expected in 2023. The company also expected to file an IND for PRX123 in 2023.
- Prothena has not obtained regulatory approval for any drug candidate and has no commercial product revenue. It expects continuing losses and substantial development expenditures.
- Major risks include clinical-trial failure or delay, regulatory uncertainty, dependence on Roche, BMS and Novo Nordisk, reliance on third-party manufacturers and clinical research organizations, intellectual-property challenges, need for additional financing and potential shareholder dilution.
- Contractual obligations included $19.7 million of operating-lease commitments, $15.7 million of supplier purchase commitments and $0.4 million of license obligations. A Brisbane facility sublease represents approximately $14.9 million of additional commitments and had not commenced for accounting purposes as of March 31, 2023.
- The company reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls as of March 31, 2023.
Most Important Facts for Investors to Verify
- Whether the projected $213 million to $229 million of 2023 net cash use and current development plans remain consistent with the $686.2 million cash balance.
- Progress, enrollment, safety and efficacy data for AFFIRM-AL, PADOVA, PRX005 and PRX012, including the expected 2023 and 2024 data readouts.
- The timing and probability of future BMS, Roche and Novo Nordisk milestones, royalties and other contingent payments; none were recognized from Novo Nordisk during the quarter.
- The extent to which R&D spending continues to accelerate and how long the stated cash runway lasts under alternative clinical-development scenarios.
- Potential dilution from future equity offerings, the at-the-market facility and outstanding equity awards.
- Manufacturing, supply-chain, regulatory, intellectual-property and third-party collaboration risks that could delay or prevent commercialization.